The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched.
Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.
With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.
"synopsis" may belong to another edition of this title.
Dr. Jorg Knablein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988).
AWARDS:
Riedel-de Haen-Stiftung
Government / Ministry of Science
Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering)
Winner of the McKinsey business plan contest
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world, including nine blockbuster drugs, and nowadays represent the mainstay products of the biotechnology industry.
This book is unique in introducing readers to a comprehensive set of recently developed technologies, showing paradigm shifts in the health care system and reflecting these changes in industrial research.
Here, the world's top scientists and business leaders divulge their first-hand expertise, allowing you to participate in their recent achievements. They all have their own specific contribution and have been carefully selected to provide a multifaceted and unique insight. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel laureates Robert Huber and Thomas R. Cech, as well as authors from the world's most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max-Planck-Institute, Fraunhofer-Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG.
The result is a testament to the importance of biotechnology in life science, a sure sign that "Modern Biopharmaceuticals" will fuel biotechnologies and help shape the industry of the future.
For pharmaceutists, pharmaceutical chemists, biochemists, molecular biologists, medicinal chemists, as well as those working in the biotechnological and pharmaceutical industries, or biotechnological institutes.
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world, including nine blockbuster drugs, and nowadays represent the mainstay products of the biotechnology industry.
This book is unique in introducing readers to a comprehensive set of recently developed technologies, showing paradigm shifts in the health care system and reflecting these changes in industrial research.
Here, the world's top scientists and business leaders divulge their first-hand expertise, allowing you to participate in their recent achievements. They all have their own specific contribution and have been carefully selected to provide a multifaceted and unique insight. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel laureates Robert Huber and Thomas R. Cech, as well as authors from the world's most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max-Planck-Institute, Fraunhofer-Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG.
The result is a testament to the importance of biotechnology in life science, a sure sign that "Modern Biopharmaceuticals" will fuel biotechnologies and help shape the industry of the future.
For pharmaceutists, pharmaceutical chemists, biochemists, molecular biologists, medicinal chemists, as well as those working in the biotechnological and pharmaceutical industries, or biotechnological institutes.
"About this title" may belong to another edition of this title.
Seller: The Book Exchange, Macclesfield, CHESH, United Kingdom
Hardcover. Condition: Fine. 352731184X. Volume 2. Pictorial board hardcover, from closed pharmaceutical company library. Lending record shows this book has never been borrowed. 342 pages, index, illustrated with charts, tables and diagrams. The biopharmaceutical market has come a long way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. The global market for biopharmaceuticals, has been growing at an impressive compound annual growth rate of 210. This segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade. Contents as new, clean, tight and bright. Volume 2 only. Book. Seller Inventory # 027098
Quantity: 1 available
Seller: The Book Exchange, Macclesfield, CHESH, United Kingdom
Hardcover. Condition: Fine. 352731184X. Volume 3; Pictorial board hardcover, from closed pharmaceutical company library. Lending record shows this book has never been borrowed. 635 pages, index, illustrated with charts, tables and diagrams. The biopharmaceutical market has come a long way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. The global market for biopharmaceuticals, has been growing at an impressive compound annual growth rate of 210. This segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade. Contents as new, clean, tight and bright. Book. Seller Inventory # 027194
Quantity: 1 available
Seller: Mispah books, Redhill, SURRE, United Kingdom
Hardcover. Condition: Like New. Like NewLIKE NEW. book. Seller Inventory # ERICA838352731184X3
Quantity: 1 available
Seller: Basi6 International, Irving, TX, U.S.A.
Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Seller Inventory # ABEOCT25-238083
Seller: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.
Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Seller Inventory # ABNR-182517
Seller: Phatpocket Limited, Waltham Abbey, HERTS, United Kingdom
Condition: Good. Your purchase helps support Sri Lankan Children's Charity 'The Rainbow Centre'. Ex-library, so some stamps and wear, but in good overall condition. Our donations to The Rainbow Centre have helped provide an education and a safe haven to hundreds of children who live in appalling conditions. Seller Inventory # Z1-V-027-02070
Quantity: 4 available
Seller: Books Puddle, New York, NY, U.S.A.
Condition: New. pp. 2022. Seller Inventory # 26250510
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. pp. 2022 Illus. Seller Inventory # 7630161
Quantity: 1 available
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New. pp. 2022. Seller Inventory # 18250500
Seller: Basi6 International, Irving, TX, U.S.A.
Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Seller Inventory # ABEOCT25-238084